KUKJEON PHARMACEUTICAL Co., Ltd (KOSDAQ:307750)
South Korea
· Delayed Price · Currency is KRW 3,585.00
-65.00 (-1.78%)
Last updated: Jun 26, 2025
KUKJEON PHARMACEUTICAL Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Operating Revenue | 135,442 | 136,468 | 121,998 | 103,711 | 85,354 |
| Other Revenue | - | -0 | - | - | -0 |
| Revenue | 135,442 | 136,468 | 121,998 | 103,711 | 85,354 |
| Revenue Growth (YoY) | 4.65% | 11.86% | 17.63% | 21.51% | - |
| Cost of Revenue | 115,377 | 114,594 | 96,721 | 84,195 | 67,409 |
| Gross Profit | 20,065 | 21,874 | 25,277 | 19,515 | 17,946 |
| Selling, General & Admin | 15,138 | 15,327 | 12,817 | 11,451 | 8,699 |
| Research & Development | 4,552 | 4,684 | 4,821 | 3,981 | 2,651 |
| Operating Expenses | 21,186 | 21,507 | 18,768 | 16,027 | 11,836 |
| Operating Income | -1,121 | 366.71 | 6,509 | 3,488 | 6,109 |
| Interest Expense | -7,773 | -8,220 | -5,735 | -1,802 | -284.47 |
| Interest & Investment Income | 431.96 | 878.98 | 1,591 | 1,037 | 208.91 |
| Earnings From Equity Investments | -114.35 | -57.48 | 1.15 | 301.09 | - |
| Currency Exchange Gain (Loss) | -978.2 | -1,655 | -253.67 | -1,215 | -869.65 |
| Other Non Operating Income (Expenses) | 11,491 | 10,498 | -391.28 | 9,279 | 196.4 |
| EBT Excluding Unusual Items | 1,937 | 1,811 | 1,722 | 11,089 | 5,360 |
| Gain (Loss) on Sale of Investments | 2,108 | 1,831 | 16.28 | 67.84 | -275.98 |
| Gain (Loss) on Sale of Assets | -49.07 | -57.43 | - | -69.18 | -0 |
| Other Unusual Items | -3,354 | -2,706 | - | - | - |
| Pretax Income | 642 | 879.32 | 1,738 | 11,088 | 5,084 |
| Income Tax Expense | 323.4 | 341.65 | -2,954 | 2,210 | 1,046 |
| Earnings From Continuing Operations | 318.6 | 537.67 | 4,692 | 8,877 | 4,038 |
| Minority Interest in Earnings | 1,123 | 1,199 | 132 | 70.7 | - |
| Net Income | 1,442 | 1,736 | 4,824 | 8,948 | 4,038 |
| Net Income to Common | 1,442 | 1,736 | 4,824 | 8,948 | 4,038 |
| Net Income Growth | 6.68% | -64.01% | -46.09% | 121.59% | - |
| Shares Outstanding (Basic) | 49 | 49 | 49 | 49 | 44 |
| Shares Outstanding (Diluted) | 49 | 49 | 49 | 51 | 44 |
| Shares Change (YoY) | 0.10% | - | -4.23% | 16.16% | - |
| EPS (Basic) | 29.35 | 35.38 | 98.31 | 182.35 | 91.54 |
| EPS (Diluted) | 29.35 | 35.38 | 98.31 | 11.35 | 91.00 |
| EPS Growth | 7.05% | -64.01% | 766.11% | -87.53% | - |
| Free Cash Flow | 3,031 | 2,169 | -44,269 | -29,304 | -7,367 |
| Free Cash Flow Per Share | 61.71 | 44.20 | -902.17 | -571.94 | -167.01 |
| Dividend Per Share | 10.000 | 10.000 | - | - | - |
| Gross Margin | 14.81% | 16.03% | 20.72% | 18.82% | 21.02% |
| Operating Margin | -0.83% | 0.27% | 5.33% | 3.36% | 7.16% |
| Profit Margin | 1.06% | 1.27% | 3.95% | 8.63% | 4.73% |
| Free Cash Flow Margin | 2.24% | 1.59% | -36.29% | -28.26% | -8.63% |
| EBITDA | 4,143 | 5,472 | 9,643 | 4,932 | 7,215 |
| EBITDA Margin | 3.06% | 4.01% | 7.90% | 4.75% | 8.45% |
| D&A For EBITDA | 5,264 | 5,105 | 3,134 | 1,444 | 1,106 |
| EBIT | -1,121 | 366.71 | 6,509 | 3,488 | 6,109 |
| EBIT Margin | -0.83% | 0.27% | 5.33% | 3.36% | 7.16% |
| Effective Tax Rate | 50.37% | 38.85% | - | 19.94% | 20.58% |
Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.